BD Life Sciences The BD Life Sciences segment provides products for the safe collection and transport of diagnostic specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, BD Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by BD Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. With the emergency use authorization approval of the BD Veritor TM At Home COVID-19 test, BD Life Sciences also serves patients directly. Key categories Leadership position 2 Biosciences • R esearch Flow Cytometry • Clinic al Flow Cytometry • Single-c ell Multiomics Integrated diagnostic solutions • Micr obiology • Specimen Management • Molec ular and Women’s Health Point of care • Pr ofessional POC Diagnostics • A t-Home Diagnostics 2 BD position based on management’s internal estimates. Includes COVID testing revenue. #1 To p 5 Flow Cytometry Single-cell Multiomics To p 2 #1 To p 5 Microbiology Specimen Management Molecular To p 5 Professional POC Diagnostics 11 2021 ESG Report Appendices Transparency Healthy workforce and communities Responsible supply chain Product impact Climate change Introduction